NO975591L - Nye imidazolinforbindelser, fremgangsmÕte ved fremstilling av dem og farmas÷ytiske sammensetninger som inneholder dem - Google Patents
Nye imidazolinforbindelser, fremgangsmÕte ved fremstilling av dem og farmas÷ytiske sammensetninger som inneholder demInfo
- Publication number
- NO975591L NO975591L NO975591A NO975591A NO975591L NO 975591 L NO975591 L NO 975591L NO 975591 A NO975591 A NO 975591A NO 975591 A NO975591 A NO 975591A NO 975591 L NO975591 L NO 975591L
- Authority
- NO
- Norway
- Prior art keywords
- halo
- phenyl
- preparation
- alkyl
- pharmaceutical compositions
- Prior art date
Links
- 150000002462 imidazolines Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 1-phenyl-1-cyclohexylmethyl Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9614844A FR2756560A1 (fr) | 1996-12-04 | 1996-12-04 | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975591D0 NO975591D0 (no) | 1997-12-03 |
| NO975591L true NO975591L (no) | 1998-06-05 |
| NO309602B1 NO309602B1 (no) | 2001-02-26 |
Family
ID=9498304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO975591A NO309602B1 (no) | 1996-12-04 | 1997-12-03 | Nye imidazolinforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5925665A (no) |
| EP (1) | EP0846688B1 (no) |
| JP (1) | JPH10168065A (no) |
| CN (1) | CN1091443C (no) |
| AT (1) | ATE189816T1 (no) |
| BR (1) | BR9706126A (no) |
| CA (1) | CA2223541A1 (no) |
| DE (1) | DE69701307T2 (no) |
| DK (1) | DK0846688T3 (no) |
| ES (1) | ES2145563T3 (no) |
| FR (1) | FR2756560A1 (no) |
| GR (1) | GR3032715T3 (no) |
| HK (1) | HK1011207A1 (no) |
| HU (1) | HUP9702341A3 (no) |
| NO (1) | NO309602B1 (no) |
| NZ (1) | NZ329312A (no) |
| PL (1) | PL323515A1 (no) |
| PT (1) | PT846688E (no) |
| ZA (1) | ZA9710918B (no) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0924209B1 (en) * | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| EP1266897A3 (en) * | 1997-12-19 | 2003-12-03 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| FR2787451B1 (fr) * | 1998-12-18 | 2001-01-26 | Adir | Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB2351082A (en) * | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
| GB2351081A (en) * | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
| GB9914255D0 (en) * | 1999-06-18 | 1999-08-18 | Lilly Forschung Gmbh | Pharmaceutical compounds |
| US20040009976A1 (en) * | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| WO2004000312A2 (de) | 2002-06-19 | 2003-12-31 | Solvay Pharmaceuticals Gmbh | Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen |
| DE10315640A1 (de) * | 2003-04-04 | 2004-10-14 | Ignatov, Konstantin | Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung |
| KR100832277B1 (ko) * | 2004-05-18 | 2008-05-26 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| CN103275011A (zh) * | 2013-06-13 | 2013-09-04 | 南京工业大学 | 咪唑烷类杂环的新合成方法 |
| KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| CN112624975A (zh) * | 2020-11-27 | 2021-04-09 | 华南农业大学 | 一种妥拉唑林半抗原、人工抗原、抗体及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140859A (en) * | 1974-11-04 | 1979-02-20 | Sandoz, Inc. | Dilithiated 2-(o-tolyl)-2-imidazolines |
| DE2854428A1 (de) * | 1978-12-16 | 1980-06-26 | Basf Ag | Verfahren zur herstellung von 2-imidazolinen |
| US4910206A (en) * | 1986-07-14 | 1990-03-20 | Sandoz Pharmaceuticals Corp. | 5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists |
| JP2545646B2 (ja) * | 1990-11-22 | 1996-10-23 | 松下電器産業株式会社 | 非線形光学材料 |
| US5574059A (en) * | 1995-10-27 | 1996-11-12 | Cornell Research Foundation, Inc. | Treating disorders mediated by vascular smooth muscle cell proliferation |
-
1996
- 1996-12-04 FR FR9614844A patent/FR2756560A1/fr not_active Withdrawn
-
1997
- 1997-12-01 JP JP9330116A patent/JPH10168065A/ja active Pending
- 1997-12-02 CA CA002223541A patent/CA2223541A1/fr not_active Abandoned
- 1997-12-02 ES ES97402891T patent/ES2145563T3/es not_active Expired - Lifetime
- 1997-12-02 AT AT97402891T patent/ATE189816T1/de not_active IP Right Cessation
- 1997-12-02 DE DE69701307T patent/DE69701307T2/de not_active Expired - Fee Related
- 1997-12-02 EP EP97402891A patent/EP0846688B1/fr not_active Expired - Lifetime
- 1997-12-02 DK DK97402891T patent/DK0846688T3/da active
- 1997-12-02 PT PT97402891T patent/PT846688E/pt unknown
- 1997-12-03 US US08/984,673 patent/US5925665A/en not_active Expired - Fee Related
- 1997-12-03 BR BR9706126A patent/BR9706126A/pt unknown
- 1997-12-03 NZ NZ329312A patent/NZ329312A/en unknown
- 1997-12-03 NO NO975591A patent/NO309602B1/no unknown
- 1997-12-03 HU HU9702341A patent/HUP9702341A3/hu unknown
- 1997-12-03 CN CN97125774A patent/CN1091443C/zh not_active Expired - Fee Related
- 1997-12-04 ZA ZA9710918A patent/ZA9710918B/xx unknown
- 1997-12-04 PL PL97323515A patent/PL323515A1/xx unknown
-
1998
- 1998-11-24 HK HK98112253A patent/HK1011207A1/xx not_active IP Right Cessation
-
2000
- 2000-02-21 GR GR20000400414T patent/GR3032715T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10168065A (ja) | 1998-06-23 |
| EP0846688A1 (fr) | 1998-06-10 |
| HUP9702341A3 (en) | 1999-04-28 |
| PT846688E (pt) | 2000-05-31 |
| CN1186074A (zh) | 1998-07-01 |
| AU4765297A (en) | 1998-06-11 |
| AU719145B2 (en) | 2000-05-04 |
| EP0846688B1 (fr) | 2000-02-16 |
| BR9706126A (pt) | 1999-05-18 |
| GR3032715T3 (en) | 2000-06-30 |
| NO975591D0 (no) | 1997-12-03 |
| HK1011207A1 (en) | 1999-07-09 |
| DE69701307T2 (de) | 2000-09-14 |
| HU9702341D0 (en) | 1998-03-02 |
| DK0846688T3 (da) | 2000-07-17 |
| ZA9710918B (en) | 1998-06-15 |
| NZ329312A (en) | 1998-07-28 |
| ATE189816T1 (de) | 2000-03-15 |
| HUP9702341A2 (hu) | 1998-07-28 |
| FR2756560A1 (fr) | 1998-06-05 |
| US5925665A (en) | 1999-07-20 |
| CA2223541A1 (fr) | 1998-06-04 |
| CN1091443C (zh) | 2002-09-25 |
| DE69701307D1 (de) | 2000-03-23 |
| NO309602B1 (no) | 2001-02-26 |
| ES2145563T3 (es) | 2000-07-01 |
| PL323515A1 (en) | 1998-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO975591L (no) | Nye imidazolinforbindelser, fremgangsmÕte ved fremstilling av dem og farmas÷ytiske sammensetninger som inneholder dem | |
| AU1358588A (en) | 4-(4-(4-((2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3- dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl) triazolones | |
| PE20050440A1 (es) | Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas | |
| FI933719A (fi) | 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol | |
| AU4029395A (en) | Use of 5-acyl-1,4-dihydropyridines | |
| AU5473596A (en) | New indole, indazole benzisoxazole compounds, their process of preparation and the pharmaceutical compositions which contain them | |
| CA2162106A1 (fr) | Nouvelles 5-(aryloxymethyl)oxazolines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HU886767D0 (en) | Process for the preparation of new 20,21-dinor-eburnamenine derivatives, new intermediates thereof, as well as pharmaceutical compositions containing said compounds as active ingredients | |
| HUT76480A (en) | Alkyl-5-methyl-sulphonyl-benzoyl-guanidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
| TW429147B (en) | Pharmaceutical composition for the treatment of CNS disorders | |
| DE59010091D1 (de) | Indolylpropanole, Verfahren zu ihrer Herstellung und ihre Verwendung sowie die Verbindungen enthaltende Zubereitungen | |
| DK0816359T3 (da) | 4-amino-2-ureido-pyrimidin-5-carboxylsyreamider, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse |